MarketCap
Facebook
X
Telegram
Ascendis Pharma A/S Balance Sheet 2025-2011 | ASND
Brief overview of Ascendis Pharma A/S's financial position
This overview follows the five latest available annual observations between 2021 and 2025.
Assets added +20.1%, reaching €1.3 billion from €1.1 billion five periods earlier; annual growth near 4.7% remained solid.
Liabilities grew faster than assets: +628% versus +20.1%. A substantial part of expansion was externally funded.
The period ended with negative equity, a structure associated with elevated financial vulnerability.
Cash equals 47.3% of the balance sheet, compared with 41.1% five periods ago. This is the readily available cushion.
Conclusion
Ascendis Pharma A/S's financial structure calls for caution. Stronger equity, lower debt or restored liquidity would be needed to improve it.
Annual Balance Sheet Ascendis Pharma A/S
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
- | - | -293 M | -336 M | - | - | - | - | -195 M | -180 M | -120 M | -50.2 M | -19.4 M | -14.3 M | -15.3 M |
Long Term Debt |
- | - | 84.6 M | 95.4 M | - | - | - | - | - | - | - | - | - | - | - |
Long Term Debt Current |
- | - | 14.2 M | 13.8 M | 7 M | 6.86 M | 5.9 M | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
396 M | 377 M | 235 M | 655 M | 101 M | 88.3 M | 31.6 M | - | - | - | - | - | - | - | 213 K |
Total Liabilities |
1.47 B | 1.29 B | 971 M | 826 M | 201 M | 141 M | 79.6 M | 38.9 M | 23.8 M | 13.5 M | 11.4 M | 12.9 M | 20.4 M | 23.8 M | 22.6 M |
Deferred Revenue |
- | - | - | - | - | 363 K | 858 K | 6.9 M | - | 94 K | 3.07 M | 7.9 M | 17.5 M | 21.1 M | 19.7 M |
Retained Earnings |
- | - | - | - | - | - | -611 M | -393 M | -263 M | 159 M | 111 M | 39.6 M | 2.13 M | -1.95 M | -3.2 M |
Total Assets |
1.3 B | 1.18 B | 826 M | 1.09 B | 1.08 B | 980 M | 677 M | 319 M | 211 M | 190 M | 132 M | 58.7 M | 26.7 M | 25.4 M | 22.8 M |
Cash and Cash Equivalents |
616 M | 560 M | 392 M | 445 M | 446 M | 585 M | 598 M | 278 M | 195 M | 180 M | 120 M | - | - | - | - |
Book Value |
-163 M | -106 M | -146 M | 263 M | 884 M | 839 M | 597 M | 280 M | 187 M | 177 M | 120 M | 45.8 M | 6.3 M | 1.56 M | 233 K |
Total Shareholders Equity |
-163 M | -106 M | -146 M | 263 M | 884 M | 839 M | 597 M | 280 M | 187 M | 177 M | 120 M | - | - | - | - |
All numbers in EUR currency
Quarterly Balance Sheet Ascendis Pharma A/S
| 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
- | - | - | - | - | 84.6 M | 84.6 M | 84.6 M | 84.6 M | 90.1 M | - | - | - | - | - | - | 98 M | 95.6 M | 94.1 M | 89.6 M | 85.1 M | 27 M | 29.1 M | 30.8 M | 30.7 M | 31.5 M | 31.5 M | 13.2 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
396 M | 342 M | 340 M | 366 M | 377 M | 353 M | 232 M | 242 M | 235 M | 734 M | 567 M | 110 M | - | - | - | 609 M | 101 M | 95.6 M | 94.1 M | 89.6 M | 88.3 M | 30.1 M | 29.1 M | 30.8 M | 31.6 M | 31.5 M | 31.5 M | 13.2 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
1.47 B | 1.33 B | 1.28 B | 1.25 B | 1.29 B | 1.19 B | 1.08 B | 1.04 B | 971 M | 947 M | 759 M | 826 M | - | - | - | 704 M | 201 M | 212 M | 164 M | 162 M | 141 M | 94.5 M | 83.5 M | 72.6 M | 79.6 M | 74 M | 92.1 M | 45.3 M | 38.9 M | 31 M | 36.6 M | 17.4 M | 23.8 M | - | - | - | 13.5 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
1.3 B | 1.15 B | 1.09 B | 1.06 B | 1.18 B | 1.09 B | 758 M | 803 M | 826 M | 873 M | 824 M | 1.09 B | - | - | - | 1.38 B | 1.08 B | 1.21 B | 852 M | 965 M | 980 M | 1.05 B | 561 M | 621 M | 677 M | 735 M | 767 M | 762 M | 319 M | 335 M | 369 M | 365 M | 211 M | - | - | - | 190 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
616 M | 539 M | 494 M | 518 M | 560 M | 626 M | 259 M | 320 M | 392 M | 441 M | 394 M | 445 M | - | - | - | 756 M | 446 M | 693 M | 385 M | 495 M | 585 M | 763 M | 241 M | 534 M | 598 M | 659 M | 690 M | 697 M | 278 M | 310 M | 353 M | 348 M | 195 M | 206 M | 127 M | 158 M | 180 M | - | - | - | 120 M | - | - | - | 50.2 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
-163 M | -174 M | -188 M | -190 M | -106 M | -97.3 M | -321 M | -238 M | -146 M | -73.4 M | 64.8 M | 263 M | - | - | - | 673 M | 884 M | 994 M | 687 M | 803 M | 839 M | 952 M | 477 M | 549 M | 597 M | 661 M | 675 M | 717 M | 280 M | 304 M | 332 M | 347 M | 187 M | - | - | - | 177 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
-163 M | -174 M | -188 M | -190 M | -106 M | -97.3 M | -321 M | -238 M | -146 M | -73.4 M | 64.8 M | 263 M | - | - | - | 673 M | 884 M | 994 M | 687 M | 803 M | 839 M | 952 M | 477 M | 549 M | 597 M | 661 M | 675 M | 717 M | 280 M | 304 M | 332 M | 347 M | 187 M | 202 M | 126 M | 155 M | 177 M | - | - | - | 120 M | - | - | - | 45.8 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in EUR currency
Balance Sheet is a fundamental financial report of Ascendis Pharma A/S, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
Canada
China
USA
France
Singapore
Britain
Germany
Israel
Russia
Belgium
Irlanda
